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Aims. Posttranslational modiﬁcations of histones and transcription factors regulate gene expression and are implicated in
beta-cell failure and diabetes. We have recently shown that preserving H3K27 and H3K4 methylation using the lysine
demethylase inhibitor GSK-J4 reduces cytokine-induced destruction of beta-cells and improves beta-cell function. Here, we
investigate the therapeutic potential of GSK-J4 to prevent diabetes development and examine the importance of H3K4
methylation for islet function. Materials and Methods. We used two mouse models of diabetes to investigate the
therapeutic potential of GSK-J4. To clarify the importance of H3K4 methylation, we characterized a mouse strain with
knockout (KO) of the H3K4 demethylase KDM5B. Results. GSK-J4 administration failed to prevent the development of
experimental diabetes induced by multiple low-dose streptozotocin or adoptive transfer of splenocytes from acutely diabetic
NOD to NODscid mice. KDM5B-KO mice were growth retarded with altered body composition, had low IGF-1 levels,
and exhibited reduced insulin secretion. Interestingly, despite secreting less insulin, KDM5B-KO mice were able to
maintain normoglycemia following oral glucose tolerance test, likely via improved insulin sensitivity, as suggested by
insulin tolerance testing and phosphorylation of proteins belonging to the insulin signaling pathway. When challenged with
high-fat diet, KDM5B-deﬁcient mice displayed similar weight gain and insulin sensitivity as wild-type mice. Conclusion.
Our results show a novel role of KDM5B in metabolism, as KDM5B-KO mice display growth retardation and improved
insulin sensitivity.
1. Introduction
Diabetes mellitus encompasses a group of chronic meta-
bolic disorders characterized by hyperglycemia. While type
1 diabetes (T1D) is characterized by absolute insulin deﬁ-
ciency, type 2 diabetes (T2D) is characterized by insulin
secretion insuﬃcient to compensate for insulin resistance
[1], stressing the importance of dysfunctional beta-cells also
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in the pathogenesis of T2D. Although T1D and T2D are
etiologically diﬀerent disease entities, in both diseases, dis-
crete genetic risk alleles are associated with functional gene
variants that regulate gene expression with impacts on islet
function and survival [2–4].
The central dogma describing the conversion of DNA to
RNA to protein has become increasingly complex over the
past decades owing to the discoveries of numerous posttran-
scriptional and posttranslational events modifying protein
production and activity. Whereas histone lysine acetylation
is typically associated with transcriptional activation, histone
lysine methylation leads to transcriptional activation or
silencing depending on which lysine residue is modiﬁed [5],
a process regulated by lysine methyl transferases and lysine
demethylases (KDMs) [6]. There are six diﬀerent KDM
families, KDMs 1 to 6, including 2-4 subtypes with diverse
functions. Most KDMs have been implicated in embryonic
development, fertility, cell diﬀerentiation, senescence, and
oncogenesis. Of particular relevance to this study, KDM5B
acts on di- and trimethylated H3K4 and interacts with gene
silencing polycomb-group (PcG) proteins [7]. In contrast,
the KDM6 family acts on di- and trimethylated H3K27,
and KDM6A regulates HOX genes controlling somatic pat-
terning during development, whereas KDM6B activates pro-
inﬂammatory cytokine gene transcription [8].
We recently demonstrated that preserving H3K27 meth-
ylation marks using the lysine demethylase (KDM) inhibitor
GSK-J4 protects beta-cells from cytokine-induced apoptosis
in rodent and human islets, possibly via reduction of NFkB
levels and ER stress signaling [9]. GSK-J4, which targets
KDM6 demethylases with the highest potency, has cross-
reactivity with the demethylase KDM5B, which catalyzes
demethylation of lysine 4 on histone 3 tail (H3K4) [9, 10].
In contrast to methylation of H3K27, methylation of H3K4
is associated with transcriptional activation and is of particu-
lar importance for transcription of essential beta-cell genes
such as ins1/2, MafA, and Glut2 [11, 12]. Accordingly,
glucose-stimulated insulin secretion (GSIS) in islets from
mice with beta-cell-speciﬁc deletion of the H3K4 methyl-
transferase Set7/9 is impaired [13]. Consistent with these
ﬁndings, we recently showed that GSK-J4 improved GSIS
accompanied by an increased level of the transcriptionally
activating H3K4 methylation mark [9], but we did not pin-
point the precise mechanism.
Previous studies have demonstrated that GSK-J4 reduces
lipopolysaccharide-induced production of proinﬂammatory
cytokines by macrophages [14] and improves experimental
autoimmune encephalomyelitis by restraining inﬂammatory
macrophage responses and inducing tolerogenic dendritic
cells, the latter promoting Treg cell activity [14, 15], sug-
gesting that GSK-J4 would ameliorate immune-mediated
diabetes. In this study, we wished to expand on our earlier
observations on the eﬀect of GSK-J4 in vitro [9] and to
explore the therapeutic potential of GSK-J4 in vivo by
assessing whether administration of GSK-J4 protects mice
from developing experimental diabetes. Furthermore, due
to the speciﬁc functions of KDM5B in gene transcription
and the importance of H3K4 methylation on islet secretory
function as reviewed above, we wished to clarify the impor-
tance of H3K4 methylation in islet function using a KDM5B
KO mouse.
2. Materials and Methods
2.1. Reagents. Two to ﬁve μg/g of the inhibitor GSK-J4
(N-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-
3-yl)-4-pyrimidinyl]-beta-alanine ethyl ester) (Tocris, #4594)
[14] or vehicle (300μl DMSO/ethanol/physiological sn) was
administered i.p. three times a week during the entire exper-
iment. A GSK-J4 stock solution of 100mM was prepared in
dimethyl sulfoxide (DMSO) to preserve stability. Before
injection, the stock solution was diluted 1 : 10 with ethanol
and brought to a ﬁnal concentration of 300-750μg/ml in
sterile physiological solution. The beta-cell-toxic compound
streptozotocin (STZ) was administered i.p. (40mg/kg) once
a day for ﬁve consecutive days to induce diabetes. STZ was
dissolved (6mg/ml) in 0.1M cold sodium citrate buﬀer,
pH4.5 immediately prior to injection.
2.2. Microarray Analysis. mRNA expression was analyzed in
INS-1 832/13 cells in the presence or absence of the KDM
inhibitor GSK-J4 (n = 7). Basic Aﬀymetrix and Experimental
Quality Analyses were performed using the Expression
Console Software v1.1.2. Probe summarization, and Data
Normalization was computed using the Robust Multiarray
Analysis (RMA) and Expression Console Software v1.4.1.46
[16]. Gene set enrichment analysis (GSEA) [17] was applied
to the expression array data using KEGG (Kyoto Encyclope-
dia of Genes and Genomes) pathways. Probes corresponding
to transcripts were used and ranked according to the t sta-
tistics in a paired t-test. GSEA was run with the highest
occurrence for genes with multiple probes and considered
pathways with 1-500 transcripts.
2.3. Mouse Genetics, Breeding, Housing, and Interventions.
To test whether in vivo administration of GSK-J4 protected
beta-cells subjected to an inﬂammatory assault, we injected
C57BL/6 mice (n = 26) with multiple low-doses of STZ on
ﬁve consecutive days in the absence or presence of GSK-J4.
The mice were divided in two groups. One group of mice
(n = 15) received GSK-J4 (2-5 μg/g; in a volume of 300μl i.p.)
starting at day -1 relative to the start of the STZ challenge
and then every other day until the end of the assay at day
17, while mice in the control group (n = 11) received an
equal volume of vehicle. Body weight was measured. At
the end of the experiment, pancreata from vehicle (n = 3)
and GSK-J4-treated (n = 4) mice were dissected and saved
for immunohistochemistry. For the evaluation of the
in vivo eﬀect of GSK-J4 in a model of autoimmune diabetes,
splenocytes from overt diabetic NOD mice were adoptively
transferred into female NODscid mice as described [18],
and the diabetes incidence was determined in vehicle
(n = 16) and GSK-J4-treated mice (n = 15). To explore the
eﬀect of GSK-J4 on insulin and glucose levels in vivo,
wild-type unchallenged C57BL/6 mice were administered
with GSK-J4 2 μg/g (n = 6) or equal amount of vehicle
(n = 4) every other day. Glycemia and insulin were measured
on day 3 after the ﬁrst GSK-J4 administration. Studies were
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approved by the Institutional Care and Use Committee
FCEyN, University of Buenos Aires. NOD/LtJ, NOD.CB17-
Prkdcscid/J (NODSCID), and C57BL/6 mice breeders were
originally purchased at The Jackson Laboratory and were
housed at IBioBA-MPSP vivarium.
To investigate the role of KDM5B, we employed a consti-
tutive whole-body KDM5B KO mouse, generated by Albert
et al. [7]. The constitutive KO mouse was generated by cross-
ing a conditional KDM5B (a.k.a. Jarid1b) [19] with Cmv-cre
transgenic mice on the BALB/c background [20] to obtain
heterozygous mice, which were further intercrossed to gener-
ate Jarid1b knockouts. Mice were kept on normal chow
(n = 9) or a high-fat western diet (HFD) (21% of the calories
from fat and 34% from sucrose) (n = 7) for 13 weeks.
Animal care and experimental procedures were carried
out in accordance with the guidelines of the Institutional Care
and Use Committee of FCEyN-Univ. of Buenos Aires. All
animals were maintained, and experiments were carried out
in accordance with the institutional guidelines and approved
by the Animal Experiments Inspectorate in Denmark.
2.4. Histological Analysis. To investigate the levels of
H3K4me3 in GSK-J4-administered mice, pancreata were dis-
sected, ﬁxed in 10% phosphate-buﬀered formalin, and dehy-
drated prior to paraﬃn embedding. Seven μm contiguous
paraﬃn sections were cut on a rotating microtome (Leica).
Insulin and H3K4me3 were detected by immunoﬂuorescence
staining. Brieﬂy, antigen retrieval with citrate buﬀer (pH = 6)
was performed on tissue sections; thereafter, sections were
permeabilized with 0.3% Triton, blocked with 1% BSA, and
incubated overnight with the following primary antibodies:
monoclonal mouse anti-insulin (1 : 200; clone HB125) and
polyclonal rabbit anti-H3K4me3 (1 : 200; ABCAM). Cell
nuclei were stained with DAPI (Invitrogen). The antigens
were visualized using Alexa Fluor 647 goat anti-rabbit or
Alexa Fluor 488 goat anti-mouse (1 : 200). All images were
digitally acquired with the same parameters and were not
further processed. The staining intensity of insulin and
H3K4me3 signal in insulin-positive cells (average ﬂuores-
cence intensity of insulin- or H3K4me3-positive area) of at
least 5 diﬀerent islets in pancreatic sections from 3 to 4 ani-
mals per group was quantiﬁed by monochromatic threshold-
ing using ImageJ image software.
For immunohistochemical analysis of pancreatic sections
from the KDM5B-KOmice, dissected pancreata were ﬁxed in
4% formaldehyde (VWR, Denmark). Paraformaldehyde-
ﬁxed pancreas tissue was embedded in paraﬃn and cut into
ﬁve μm sections using a microtome. Pancreatic tissue (one
randomly selected representative section/pancreas)was coim-
munostained with glucagon antiserum diluted 1 : 15,000
(ab4304 raised in rabbit) and insulin antiserum diluted
1 : 3,000 (HUI-018 nn raised in mouse). The kit Multivision
Polymer Detection System from Thermo Scientiﬁc (cat. no.
TL-012-MHRA) was used to visualize the presence of two
proteins simultaneously. The sections were incubated with
the primary antibodies overnight at 4°C, immunohistochem-
istry was performed using a biotinylated secondary antibody
and a streptavidin biotin conjugate, and the reactions were
visualized using diaminobenzidine. Sections were counter-
stained with hematoxylin. The relative area of immunoreac-
tive cells was measured in six randomly selected islets per
section in a blinded manner. All measurements were per-
formed on images using the software Zen Black.
2.5. Islet Isolation. Pancreatic islets were isolated mice
(n = 3‐4) by bile duct perfusion of the pancreas with Liberase
(Roche, Hvidovre, Denmark). Digestion was stopped by the
addition of HBSS buﬀer containing Mg2+ and Ca2+ (Gibco),
3 g/l BSA, and 0.5 g/l D-glucose and washed with HBSS three
times. Islets were handpicked under a dissection microscope
and cultured for 1 day in RPMI 1640 with GlutaMax (Gibco-
BRL, DK), supplemented with 100U/ml penicillin and
100 μg/ml streptomycin, and 10% FCS (Gibco-BRL, DK).
2.6. Glucose-Stimulated Insulin Secretion. For each condition,
25 islets were transferred to medium containing 3.0mM glu-
cose for 3 hours to establish baseline insulin secretion. Next,
25 islets per condition were incubated for 30min at 37°C in
3.0mM Krebs-Ringer solution (pH7.4, 0.1% BSA, 0.1mM
HEPES) followed by 30min at 37°C in 17mM Krebs-Ringer
solution. Supernatants from both conditions were kept for
insulin measurement. Insulin was measured using the Sensi-
tive Insulin RIA kit (Linco Research).
2.7. Body Composition. Body weight was measured at indi-
cated time points in young and aged female mice (n = 5‐8),
and body composition was determined in unanesthetized
mice at indicated ages by quantitative magnetic resonance
imaging (MRI) using EchoMRI 4-in-1 (Echo Medical Sys-
tems, Houston, TX). Body length between nose and tail root
was measured in anesthetized mice (n = 2‐4). Mice were
sacriﬁced, and the right femur bone was excised. After care-
fully removing all adhering soft tissues, the length (mm)
between the greater trochanter and medial condyle was mea-
sured (n = 5).
2.8. Metabolic Phenotype. Oral glucose tolerance tests
(OGTT) were carried out in female mice at indicated ages.
Mice were fasted for 16–18 hours with free access to water.
Glucose (1.5 g/kg body weight) was administered by oral
gavage. Concentration of blood glucose was measured at time
points -30, 0, 15, 30, 60, and 120min, using a glucometer
(Ascensia Elite XL Diabetes Care System; Bayer HealthCare,
Berkeley, CA). At time points -30 and 15min, blood was col-
lected from the orbital sinus for insulin measurement mea-
sured using the sensitive insulin mouse radioimmunoassay
(RIA) kit (Linco Research). For insulin tolerance test (ITT),
mice were fasted for 2 hours with free access to water. Mice
were challenged with insulin i.p. (Actrapid; Novo Nordisk,
Copenhagen, Denmark) at a dose of 0.75U/kg. Blood glucose
levels were monitored as in the OGTT.
2.9. Measurement of Growth Hormone (GH) and Insulin-Like
Growth Factor-1 (IGF-1). Plasma levels of GH and IGF-1
were measured in female mice (n = 4‐6) at indicated
ages. After overnight fast, blood was collected from the
orbital sinus and plasma was separated for the measurement
of IGF-1 using the ACTIVE Mouse/Rat IGF-1 RIA kit
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(Diagnostic Systems Laboratories Inc.). Plasma GH was
measured using the Rat/Mouse GH ELISA Kit (Millipore).
2.10. Western Blotting. Gastrocnemius or soleus muscles
were dissected from mice (n = 4‐5) at age 37-42 weeks and
homogenized in lysis buﬀer. The homogenate was centri-
fuged at 16,000 g for 20min, and the supernatant was used
for western blot analyses. Protein concentration in lysates
from skeletal muscle was determined using the BCA protein
kit (#23225, Pierce), and equal amount of proteins were
diluted in NuPage LDS sample buﬀer (#NP0007, Life Tech-
nologies) containing 50mM DTT and heated to 92°C for
5min. 15 μg protein per lane was separated on 4-12%
Bis-tris gels (Life Technologies) and electroblotted to PVDF
membranes (#88518, Thermo Scientiﬁc). The membranes
were blocked for 30min (#37543, Thermo Scientiﬁc) before
incubating membrane with primary antibody diluted 1 : 1000
overnight at 4°C. Antibodies to phospho-GSK3beta (#9315),
total GSK3beta (#9336), phospho-Akt (#9271), total Akt
(#9272), GAPDH (#2118), and IRbeta (#3020) were obtained
from Cell Signaling. The membranes were washed in PBS +
0.1% tween-20 and incubated for 1 hour at room temperature
with a horseradish peroxidase- (HRP-) conjugated secondary
antibody (anti-mouse IgG #7076 or anti-rabbit IgG #7074
from Cell Signaling). After three washes, the membranes
were incubated for 5min with chemiluminescent HRP
substrate luminol (#WBKLS0500, Millipore) and visualized
using the FlourChem E Imaging System (ProteinSimple,
San Jose, CA). The bands were quantiﬁed using ImageJ.
2.11. Statistical Analysis. Results are presented as means +
SEM. Statistical signiﬁcance (p < 0 05) was determined using
GraphPad Prism 6 software by one- or two-way ANOVA as
indicated or Student’s t-test for paired or unpaired compari-
sons of two conditions. For statistical analyses of microarray
data, t-test and statistical analysis of microarray (SAM) anal-
ysis were performed to identify signiﬁcantly diﬀerentially
expressed genes between groups [21] using TMEV v4.0 soft-
ware, and false discovery rate (FDR) was applied to account
for multiple testing.
3. Results
3.1. GSK-J4 Does Not Prevent or Delay Hyperglycemia in
Diabetes Mouse Models. We have previously shown that
GSK-J4 protects rodent and human beta-cells from destruc-
tion caused by proinﬂammatory cytokines in vitro [9].
Therefore, we wished to address whether GSK-J4 adminis-
tration might exert similar beneﬁcial eﬀects in vivo in the
multiple low-dose STZ model of autoimmune diabetes.
The mice tolerated GSK-J4 well, and there was no diﬀer-
ence in body weight between groups (Figure 1(a)). GSK-
J4 resulted in increased levels of H3K4me3 measured in
pancreatic sections, indicating inhibition of KDM5B as
intended (Figures 1(b) and 1(c), p = 0 057). GSK-J4 did
however not inhibit or attenuate multiple low-dose STZ-
induced hyperglycemia (Figures 1(e) and 1(f)).
Adoptive transfer of diabetogenic splenocytes from
overtly diabetic NOD mice into NODscid mice is a more
stringent model of autoimmune diabetes [22]. However,
GSK-J4 administration did not have any eﬀect on the time
of onset or diabetes frequency when compared to control
mice (Figure 1(g)). Taken together, these data demonstrate
that in vivo GSK-J4 administration fails to inhibit immune-
mediated diabetes development.
3.2. GSK-J4 Upregulates Gene Sets Comprising Olfactory and
Glutamate Receptors. Being unable to prevent the develop-
ment of STZ-induced or adoptive transfer of autoimmune
diabetes by in vivo administration of GSK-J4, we pursued
the previous observation of increased insulin secretion fol-
lowing GSK-J4 exposure in vitro [9]. To investigate whether
we could reproduce our ﬁndings in vivo, we administered
GSK-J4 to normal, unchallenged C57BL/6 mice and mea-
sured plasma insulin following three days. There was no
change in glycemic levels (Figure 1(h)), but we were able to
reproduce our in vitro ﬁndings and observed signiﬁcantly
increased levels of insulin following in vivo administration
of GSK-J4 (Figure 1(i)). Pancreatic islet insulin staining was
slightly but nonstatistically increased in GSK-J4-exposed
mice (Figures 1(b) and 1(d)). To dissect the mechanism
behind this observation, we applied gene set enrichment
analysis (GSEA) on microarray data obtained from the
beta-cell line INS-1 832/13 cells exposed to vehicle or GSK-
J4 for 24 hours. After false discovery rate (FDR) correction
of the microarray data, the GSEA yielded two signiﬁcantly
upregulated gene sets (q = 0 0001) containing genes involved
in “olfactory transduction” and “neuroactive ligand-receptor
interaction” (Supplementary Table 1). Genes contributing to
the enrichment for the signiﬁcant gene set “neuroactive
ligand-receptor interaction” include genes encoding both
ionotropic and metabotropic glutamate receptors.
3.3. KDM5B-KO Mice Have Enlarged Islets of Langerhans
with an Increased Islet Insulin-Positive Area. Knowing that
H3K4 methylation is important for the transcription of
beta-cell genes and insulin secretion [12, 13], we considered
it likely that the GSK-J4-induced improved insulin secretion
was primarily achieved via KDM5B inhibition and thereby
preservation of H3K4 methylation. To investigate the impor-
tance of H3K4 methylation on islet function, we employed a
whole-body KDM5B-KO mice [7].
We initiated our study by investigating islet morphology.
Whole pancreata were dissected from KDM5B-KOmice, and
immunohistochemical analyses were conducted on pancre-
atic sections. Islet morphology from KDM5B-KO mice
resembled islets from wild-type (WT) mice (Supplementary
Figure 1A). However, quantifying the area of randomly
selected islets from the pancreatic sections showed that
the insulin-positive area per islet from KDM5B-KO mice
was signiﬁcantly higher than from WT mice (p < 0 01)
(Figure 2(a)), and likewise for the glucagon-positive area per
islet, although not signiﬁcantly (p = 0 070) (Figure 2(b)). The
ratio of beta/alpha cell area showed no diﬀerence between
WT and KO mice (Figure 2(c)). The islet area of KDM5B-
KO mice tended to be larger than that of WT (Figure 2(d)),
and when we examined the size distribution of the islets,
KDM5B-KO mice had a signiﬁcantly higher number of
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large islets (>20,000 μm2) compared to WT mice (p < 0 05)
(Figure 2(e)).
3.4. KDM5B-KO Mice Maintain Normoglycemia despite
Impaired Insulin Secretion. Having observed enlarged islets
with an increased insulin-positive area per islet, we continued
investigating our hypothesis that KO of KDM5B improved
insulin secretion by maintaining higher levels of H3K4 meth-
ylation. Surprisingly, glucose-stimulated insulin secretion
conducted on islets ex vivo revealed that KDM5B-KO mouse
islets were incapable of signiﬁcantly increasing their insulin
secretion in response to high glucose in contrast to islets from
WT mice (Figure 3(a)), despite similar levels of insulin con-
tent (Supplementary Figure 2A). Furthermore, following
in vivo glucose challenge, young KDM5B-KO mice aged
approximately 9 weeks secreted signiﬁcantly less insulin
compared to WT mice (p < 0 01) (Figure 3(b)). However,
despite secreting less insulin, KDM5B-KO mice were able
to maintain normoglycemia following an oral glucose
tolerance test (OGTT), indicating improved insulin
sensitivity (Figure 3(c)). Interestingly, insulin tolerance test
(ITT) showed that recovery after hypoglycemia was delayed
in KDM5B-KO mice (p < 0 05) (Figure 3(d)), supporting
that KDM5B-KO mice maintain normoglycemia through
improved insulin sensitivity.
3.5. KDM5B-KO Mice Display Reduced Growth. We next
examined the eﬀect of KDM5B-KO on body weight and
composition by MRI on young mice of approximately 9
weeks of age. KDM5B-KO mice had a signiﬁcantly lower
body weight (p < 0 05) (Figure 3(e)). Absolute weight of lean
mass was reduced (p < 0 01) (Supplementary Figure 2B),
which following normalization to the body weight
resulted in a relative lean mass similar to that of WT
mice (Supplementary Figure 2C). The absolute weight of
fat mass was similar between WT and KDM5B-KO mice
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(Supplementary Figure 2D), revealing a fat accumulation in
KDM5B-KO mice (p < 0 05) following normalization to
body weight (Supplementary Figure 2E).
With increasing age (from approximately 10 weeks of
age to 32 weeks of age), percentage of body fat was nor-
malized becoming similar to that of WT mice and likewise
for percentage of lean mass (Supplementary Figures 3A-3B).
Absolute fat mass was furthermore unchanged, while
absolute lean mass correlated with the decreased body
weight and was signiﬁcantly reduced (p < 0 01)
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Figure 2: (a-d) The relative fraction of insulin- or glucagon-positive cells, ratio of β/α cells, and area of immunoreactive cells were measured
in six randomly selected islets per section. (e) Quantiﬁcation of area of all islets in each section using the software Zen Black. Results are shown
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(Supplementary Figures 3C-3D). Distribution of gonadal,
subcutaneous, and retroperitoneal fat was similar between
WT and KDM5B-KO mice (Supplementary Figures 3E-
3G). Interestingly, the mice aged 30-35 weeks maintained a
reduced body weight (p < 0 05) (Figure 4(a)), which was
accompanied by a signiﬁcant reduction in body length
(p < 0 01) and femoral bone length (p < 0 05) (Figures 4(b)
and 4(c)) indicating a more general growth retardation. To
investigate whether the impaired growth observed in
KDM5B-KO mice was associated with impaired growth
hormone (GH) action, we measured the levels of GH,
insulin-like growth factor- (IGF-) 1, and liver weight in
mice aged 30-35 weeks. GH levels tended to be reduced
both in plasma and pituitary (p = 0 082, p = 0 077)
(Figures 4(d) and 4(e)), and we observed a signiﬁcant
reduction in liver weight and levels of IGF-1 in plasma
(p < 0 05) (Figures 4(f) and 4(g)). Taken together, these
data show that lack of KDM5B leads to growth retardation.
3.6. Normoglycemia Observed in KDM5B-KO Mice Is
Accompanied by Increased Insulin Signaling. While reduced
somatic growth was observed in KDM5B-KO mice through-
out life, we observed a diﬀerence in the percentage of fat mass
between mice of 7-11 weeks and 30-35 weeks of age. We
therefore wished to investigate the metabolic phenotype in
KDM5B-KO mice aged 30-35 weeks to assess their glucose
tolerance. Following oral glucose challenge, we saw an
even more pronounced reduction in insulin secretion in
KDM5B-KO aged 30-35 weeks compared to younger mice
(p < 0 001) (Figure 4(h)). Despite the gross lack of insulin,
the KDM5B-KO mice aged 30-35 weeks maintained normo-
glycemia following glucose challenge as did young mice
(Figure 4(i)). ITT showed a delayed counter-regulatory
response 30-60min following insulin challenge, although
AUC was not signiﬁcantly reduced (p = 0 099) (Figure 4(j)).
To elucidate the mechanism by which KDM5B-KO mice
maintain normoglycemia despite secreting less insulin, we
investigated the components of the insulin signaling pathway
in skeletal muscle. The insulin receptor- (IR-) beta was unaf-
fected by KDM5B-KO (Supplementary Figure 3H), but
interestingly, phosphorylation of Akt and glycogen synthase
kinase- (GSK-) 3beta was signiﬁcantly increased in skeletal
muscle from KDM5B-KO mice (Figures 4(k)–4(n)), further
suggesting improved insulin sensitivity.
3.7. KDM5B-Deﬁcient Mice Maintain Reduced Body Weight
and Normoglycemia When Challenged with High-Fat Diet.
Having found that KDM5B-KO improves glucose tolerance
and insulin sensitivity when fed normal chow diet, we next
wished to investigate whether KDM5B-KO might have the
potential to improve glucose tolerance in a T2D model. To
do this, we used the high-fat diet (HFD) model causing
impaired glucose tolerance and T2D [23]. We were unable
to breed a suﬃcient number of homozygous knockout mice
due to high neonatal mortality resulting from respiratory fail-
ure, so the HFD cohort consisted of WT and heterozygous
KDM5B-deﬁcient mice.
At baseline, the KDM5B-deﬁcient mice exhibited
decreased body weight (p < 0 05) (Figure 5(a)). They were
equally susceptible to HFD-induced weight gain as WT
mice and thus maintained a decreased body weight during
13 weeks of HFD (Figure 5(b)). The percentage of fat and
lean mass was decreased and increased in KDM5B-deﬁcient
mice compared to WT mice, respectively (Supplementary
Figures 4A-4B). The relative fat mass increased over time
but was signiﬁcantly decreased compared to WT mice
(Supplementary Figure 4C), while there was no diﬀerence
in the relative lean mass between KDM5B-deﬁcient and
WT mice following HFD (Supplementary Figure 4D).
We further investigated the impact of HFD on the met-
abolic phenotype of the mice. Following glucose challenge,
there was no diﬀerence in insulin secretion of KDM5B-
haploinsuﬃcient mice compared to WT mice (Figure 5(c)),
as we had observed in KDM5B-KO mice fed normal chow
(Figure 3(b) and Figure 4(h)). The blood glucose levels of
KDM5B-deﬁcientmice were similar to those ofWTmice dur-
ing OGTT (Figure 5(d)), and there was no diﬀerence between
WT and KDM5B-deﬁcient mice when conducting ITT
(Figure 5(e)). There was furthermore no diﬀerence in the
levels of plasma GH or IGF-1 following HFD (Supplementary
Figures 4E-4F).
4. Discussion
In this study, we wished to investigate the eﬀect of lysine
demethylase inhibition in vivo on experimental diabetes
and elucidate the speciﬁc role of KDM5B on insulin secre-
tion. While in vivo administration of the pharmacological
inhibitor GSK-J4 failed to prevent the development of auto-
immune diabetes, our ﬁndings suggest that KDM5B plays
an important role in regulating somatic growth as well as
maintaining glucose homeostasis in vivo.
KDM5B has been shown to be important for respiratory
and neural developmental processes in mice [7, 19], but the
role of KDM5B in beta-cell function has not previously been
elucidated. Here, we show that KDM5B-KO resulted in
enlarged islets of Langerhans with an increased fraction of
beta-cell area compared to WT mice. Despite secreting less
insulin than WT mice, KDM5B-KO mice were able to main-
tain normoglycemia following OGTT conducted at diﬀerent
ages. ITT showed indications of improved insulin sensitivity,
and western blot analysis conducted in skeletal muscles
revealed increased phosphorylation of proteins involved in
the insulin signaling pathway suggesting an increased activ-
ity. KDM5B-KO mice furthermore displayed reduced
somatic growth and alterations in body composition at dif-
ferent ages, associated with reduced GH action. When chal-
lenged with HFD, Kdm5b-deﬁcient mice maintained the
baseline reduction in body weight but were not protected
against HFD-induced weight gain and responded similarly
as WT mice regarding blood glucose levels.
We have previously shown that the KDM inhibitor
GSK-J4 improves GSIS in vitro [9]. Here, we show GSK-
J4 also potentiates insulin secretion in vivo, associated with
increased pancreatic islet H3K4me3 levels. From GSEA,
we show that GSK-J4 leads to signiﬁcant upregulation of
genes belonging to olfactory receptors and glutamate recep-
tors. Interestingly, a recent study reveals that pancreatic islets
9Journal of Diabetes Research
WT HET KO
0
10
20
30
40
Bo
dy
 w
ei
gh
t (
g)
⁎
(a)
WT HET KO
8
9
10
11
Bo
dy
 le
ng
th
 (c
m
) ⁎⁎
(b)
WT KO
0.0
0.5
1.0
1.5
2.0
Fe
m
or
al
 le
ng
th
 (c
m
)
⁎
(c)
WT KO
0.0
0.5
1.0
1.5
2.0
Pl
as
m
a G
H
 (n
g/
m
l)
p = 0.082
(d)
WT KO
0
10
20
30
40
p = 0.077
Pi
tu
ita
ry
 G
H
 (n
g/
m
l)
(e)
WT HET KO
0.0
0.5
1.0
1.5
2.0
Li
ve
r w
ei
gh
t (
g)
⁎
(f)
WT KO
0
50
100
150
200
Pl
as
m
a I
G
F-
1 
(n
g/
m
l)
⁎
(g)
0
2000
4000
6000
WT HET KO
Pl
as
m
a i
ns
ul
in
 (n
g/
m
l)
0 
m
in
15
 m
in
15
 m
in
15
 m
in
0 
m
in
0 
m
in
⁎⁎⁎
(h)
Figure 4: Continued.
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and a beta-cell line exhibit the expression of olfactory recep-
tors and that these receptors promote GSIS possibly via the
phospholipase C-inositol triphosphate (PLC) pathway [24].
Furthermore, glutamate has been found to act as an excit-
atory neurotransmitter in the islets leading to improved
insulin secretion [25, 26]. The mechanisms behind GSK-
J4-mediated improved GSIS might thus involve increased
expression of olfactory and glutamate receptors, leading
to potentiated signaling for insulin secretion.
Methylation of H3K4 is important for the transcription
of essential beta-cell genes [12, 27, 28], and preserved H3K4
methylation is associated with improved insulin secretion
[13, 29]. We therefore hypothesized that preservation of
H3K4 methylation achieved by KO of KDM5B would
improve beta-cell function. In contrast to our expectations,
GSIS conducted in islets from KDM5B-KO mice revealed
reduced insulin secretion following the glucose challenge.
Immunohistochemical analysis of pancreatic sections
showed that KDM5B-KO mice exhibited a higher number
of enlarged islets compared to WT mice.
Studies showing that knockdown or knockout of H3K4
methyltransferases leads to decreased expression of featured
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Figure 4: Phenotypic characterization of KDM5B-KO mice aged 30-35 weeks. (a) Body weight (g) (n = 5‐8). (b) Body length was measured
between nose tip and tail root in anesthetized female mice (n = 2‐4) of 30-35 weeks of age. (c) Femoral length (cm) (n = 5) and representative
image from a WT and a KO. (d) Plasma GH levels (n = 4‐6). (e) Pituitary GH levels (n = 3‐5). (f, g) Liver weight (n = 5‐8) and plasma IGF-1
levels (n = 4‐6) were measured in female mice of age 37-42 weeks. (h, i) OGTT. Female mice (n = 5‐8) aged 30-35 weeks were fasted overnight
(16-18 hours) with access to water ad libitum. Blood samples were taken from a tail puncture at the indicated time points for measurement of
glucose. (h) For measurement of insulin, a blood sample was taken from orbital sinus at time points -30 and 15min for each genotype during
OGTT. (i) Glucose excursion curves are shown for each genotype. AUC is shown for comparison of diﬀerences in glucose excursions. (j) ITT.
Female mice (n = 5‐8) aged 30-35 weeks were fasted 2 hours prior to ITT with access to water ad libitum. Insulin was injected i.p. at dosage
0.75U/kg body weight. (k-n) Protein expression levels of Akt and GSK-3β as determined by quantiﬁcation of western blots onmuscle samples
from female mice (n = 4‐5) of age 37-42 weeks. Results are shown as means + SEMs. Statistical signiﬁcance was determined by two-way
ANOVA with Tukey’s multiple comparison test. Results are shown as means + SEMs. Statistical signiﬁcance was determined by unpaired t
-test, one-way or two-way ANOVA. ∗p < 0 05, ∗∗p > 0 01, and ∗∗∗p < 0 001.
11Journal of Diabetes Research
beta-cell genes and impaired GSIS via decreased H3K4 meth-
ylation have either been carried out in beta-cell lines, islets, or
in mice with beta-cell-speciﬁc knockout [12, 13, 27, 28]. As
our study was performed in a constitutive whole-body
KDM5B-KO mouse, secondary pathology derived from the
eﬀects of the knockout on other cell types than islets most
likely takes place, e.g., on the IGF-2 expression in the liver
and many other tissues as detailed below. It is therefore pos-
sible that KDM5B-KO increases proliferation yielding large
islets, with lower secretory capacity than small islets [30, 31]
or nonproliferating beta-cells [32], thereby abrogating any
positive eﬀect of KDM5B-KO on insulin secretion. In accor-
dance, it has been shown that the H3K4 methyltransferase
SETD1A catalyzes methylation of heat-shock protein 70
(HSP70), leading to nuclear localization and growth promo-
tion via direct interaction with Aurora kinase B [33]. Finally,
it should be kept in mind that compensatory upregulation of
other KDMs may confound the phenotype, e.g., KDM5A
which regulates diﬀerentiation, cell cycle, and mitochondrial
function, and KDM5C which controls neuronal function
and viability.
Interestingly, we found that KDM5B-KO mice were able
to compensate for the decreased insulin secretion by improv-
ing insulin sensitivity and thus maintained normoglycemia
following OGTT. This ﬁnding is in accordance with studies
showing that mice with deletion of the H3K4 methyltransfer-
ase Set7/9 display glucose intolerance [13], while mice deﬁ-
cient in another H3K4 methyltransferase myeloid-lineage
leukemia (Mll2) display impaired glucose tolerance and insu-
lin resistance [29].
Binding of insulin to its receptor initiates a signaling
cascade resulting in glucose uptake in target tissues [34].
Following recruitment and phosphorylation of substrate
molecules, e.g., insulin receptor substrate 1 and 2 (IRS1 and
WT HET
0
5
10
15
20
25
Bo
dy
 w
ei
gh
t a
t b
as
eli
ne
 (g
) ⁎
(a)
Weeks on HFD
WT
HET
2 4 6 8 10 12 14
15
20
25
Bo
dy
 w
ei
gh
t (
g)
30
⁎⁎
(b)
WT HET WT HET
0
250
500
750
1000
1250
NS
Baseline 15 min post glucose
Pl
as
m
a i
ns
ul
in
 (p
g/
m
l)
(c)
−30 0 30 60 90 120
0
10
20
30
Time after glucose (min)
OGTT - HFD
Bl
oo
d 
gl
uc
os
e (
m
M
)
WT
HET
(d)
−30 0
WT
HET
30 60 90
Time after insulin (min)
120 150 180
0.0
2.5
5.0
7.5
Bl
oo
d 
gl
uc
os
e (
m
M
) 10.0
12.5
ITT - HFD
(e)
Figure 5: HFD cohort–phenotypic characterization. Wild-type (n = 9) and haploinsuﬃcient mice (n = 7) were fed HFD (consisting of 60% fat
compared to 11% in normal chow) for 13 weeks from age of 2-5 weeks. (a) Body weight at day 0 of HFD diet. (b) Body weight during 13 weeks
of HFD. (c, d) OGTT. Following 13 weeks of HFD, mice were fasted overnight (16-18 hours) with access to water ad libitum. Blood samples
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IRS2), activation of the downstream kinase serine/threonine
protein kinase B (Akt/PKB) causes translocation of GLUT4
to the plasma membrane as well as phosphorylation and
inactivation of glycogen synthase kinase-3beta (GSK-3beta)
[35]. Inactivation of GSK-3beta removes the inhibitory phos-
phorylation of glycogen synthase (GS) thereby promoting
synthesis of glycogen [36]. Several of these components
have been shown to be regulated by lysine acetylation, as
KDAC inhibitors leads to increased IRS2 expression, activ-
ity of IRS1 and Akt, and transcription of GLUT4 [37].
Our ﬁndings suggest that lysine demethylases play a similar
regulatory role, as we found phosphorylation of Akt and
GSK-3beta to be increased in the KDM5B-KO mouse. Such
a regulatory role of lysine demethylases is supported by
other studies [38–40].
The GH-IGF-1 axis is of particular importance for deter-
mining body length by stimulating linear bone growth [41,
42]. In accordance, we found the reduced body weight and
length of KDM5B-KO mice to be associated with decreased
GH and IGF-1 levels. Although we did not measure IGF-2
levels, it is possible that a compensatory upregulation of
IGF-2 takes place. IGF-2 is mainly important for fetal
growth, and does not compensate for reduced growth caused
by GH and IGF-1 deﬁciencies in adult life [43]. However,
since IGF-2 acts on the pancreatic beta-cells, an upregulation
of IGF-2 would support beta-cell proliferation, which would
explain the increased size and insulin-positive area as
observed in islets from KDM5B-KO mice. In fact, IGF-2 is
intricately regulated by imprinting and epigenetic control
[44]. Deﬁciency of GH is furthermore associated with
reduced growth, fat accumulation, and increased insulin
sensitivity [45]. Interestingly, mice deﬁcient in PICK1, a
protein important for general vesicle biogenesis, are also
deﬁcient in GH [46] and display reduced growth, fat accu-
mulation, and improved insulin sensitivity. As we observed
similar phenotypical characteristics in KDM5B-KO mice,
methylation may regulate transcription of GH or activity
of the GH receptor signaling, as observed with other hor-
mone receptors [47].
In summary, our ﬁndings reveal a novel role of KDM5B
in body growth and metabolism, as KDM5B-KO reduced
body weight and length and improved insulin sensitivity.
The repressive eﬀect of KDM5B on gene transcription, which
is essential in order to avoid inappropriate gene expression
during embryonic development [7], might have undesired
eﬀects later in life and inappropriately shut oﬀ the expression
of genes involved in beneﬁcial metabolic pathways. While the
role of KDM5B in beta-cell function should be further exam-
ined, e.g., by creating a beta-cell-speciﬁc KO mouse, the
beneﬁcial eﬀects of KDM5B-KO on insulin sensitivity should
be assessed by investigating the expression and function of
KDM5B in insulin-sensitive tissues.
Data Availability
The data used to support the ﬁndings of this study are
included within the article as well as within the supplemen-
tary information ﬁle.
Conflicts of Interest
We declare no conﬂict of interest that could be perceived as
prejudicing the impartiality of the research reported.
Acknowledgments
We thank Heidi Marie Paulsen for technical assistance in
preparing pancreatic sections. We further thank Jeppe
Hvidtfeldt Ekberg and Anette Bjerregaard for measuring
insulin, GH, and IGF-1. This work was supported by a
SHARE 2012 PhD Fellowship, the Augustinus Fonden, the
Arvid Nilssons Fond, the Aase and Ejnar Danielsen Founda-
tion, the Novo Nordisk Fonden, the Swedish Research
Council, the European Research Council (PAINTBOX,
NO 725840), Exodiab, Region Skåne (ALF), the Swedish
Foundation for Strategic Research for IRC15-0067, and the
Swedish Diabetes Foundation.
Supplementary Materials
Supplementary 1. Supplementary Figure 1. (A) Representa-
tive images of islet morphology. Pancreatic tissues were
dissected from wild-type (WT) (n = 8), haploinsuﬃcient
(heterozygous, HET) (n = 6), and knockout (KO) (n = 3)
mice, and islets were immunostained with either insulin
(brown) or glucagon (blue) antibodies.
Supplementary 2. Supplementary Figure 2. (A) Insulin con-
tent measured ex vivo following GSIS (n = 3‐4). Results are
shown as means + SEMs. Statistical signiﬁcance was deter-
mined by unpaired t-test. (B-E) Absolute and relative lean
and fat mass was determined in unanesthetized female mice
(n = 5‐8) of age 7-11 weeks using a magnetic resonance imag-
ing (MRI) scanner. Results are shown asmeans + SEMs. Sta-
tistical signiﬁcance was determined by one-way ANOVA.
∗p < 0 05, ∗∗p < 0 01.
Supplementary 3. Supplementary Figure 3. (A-D) Absolute
lean and fat mass was determined in unanesthetized female
mice (n = 5‐8) of age 30-35 weeks using a MRI scanner.
(E-G) Following sacriﬁce, weight of gonadal, subcutaneous,
and retroperitoneal fat tissue was measured and normalized
to body weight. (H) Protein expression levels of IR-β was
determined by quantiﬁcation of western blots on muscle
samples from female mice (n = 4‐5) of age 37-42 weeks.
Results are shown as means + SEMs. Statistical signiﬁcance
was determined by one-way ANOVA. ∗∗p < 0 01.
Supplementary 4. Supplementary Figure 4. Wild-type (n = 9)
and heterozygous mice (n = 7) were fed HFD for 13 weeks
from the age of 2-5 weeks. (A-D) Absolute and relative fat
and lean mass during 13 weeks of HFD. (E-F) GH and
IGF-1 levels were measured in plasma from mice of age
23-26 weeks. Results are shown as means + SEMs. Statistical
signiﬁcance was determined using two-way ANOVA or
unpaired t-test. ∗∗p < 0 01.
Supplementary 5. Supplementary Table 1. Expression data
from INS-1 832/13 cells in the absence or presence of the
inhibitor GSK-J4. GSEA yielded two gene sets with upregu-
lated expression.
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